HOME > TOP STORIES

TOP STORIES

REGULATORY PMDA Updates Veklury Label to Allow Its Use in Moderate COVID-19

January 8, 2021
ORGANIZATION Japan Pharma Lobbies Shifting to Manabe/Okada Leadership? Their Abilities Will Be Tested as Industry Grapples with Thorny Issues

January 7, 2021
ACADEMIA Japan Reports Mother-to-Infant Cervical Tumor Transmission via Amniotic Fluids

January 7, 2021
BUSINESS Drug Makers, Wholesalers Brace for Second Emergency Declaration in Japan

January 6, 2021
ORGANIZATION 5% Discrepancy Line a Bad Surprise, FPMAJ Exec Says Drug Prices Will Now Go Down at Double Speed with Annual Re-Pricing

January 5, 2021
REGULATORY Govt Eager to Roll Out 1st COVID-19 Vaccine by Late February; PM Says Pfizer’s Japan Data Ready by Month-End

January 5, 2021
COMMENTARY Japan Rushing to Build COVID-19 Vaccination Regime as 1st Approval Draws Near

December 28, 2020
TRENDS Top 10 PHARMA JAPAN Articles in 2020

December 28, 2020
BUSINESS AstraZeneca to Accelerate Growth of Forxiga with Heart Failure Use, Gets Head Start in Arena before Rival Jardiance

December 28, 2020
REGULATORY MHLW Approves Label Expansions for Olumiant, Gardasil, Lynparza and More

December 28, 2020
BUSINESS Kobayashi Kako Recalls 12 More APIs after On-Site Inspections

December 25, 2020
BUSINESS Daiichi Sankyo Espha Stops Supply of 3 APIs after Kobayashi Kako Mix-up

December 25, 2020
BUSINESS 49 APIs Listed in 2020, 10 Billion-Plus Yen Peak Sales Projected for 17: Jiho Tally

December 24, 2020
ACADEMIA Alvesco Fails in COVID-19 Trial, NCGM Says It Can’t Be Recommended

December 24, 2020
REGULATORY Results of On-Site Probe into Kobayashi Kako Due Out Early Next Year, MHLW Eyes Biz Suspension

December 24, 2020
BUSINESS Axcelead Looks to Unearth New Drugs from Takeda’s Legacy Assets, 5-Plus Collaborations Ongoing

December 23, 2020
BUSINESS Meiji, Again, Halts Supply of Kobayashi Kako-Made Drugs after On-Site Inspections

December 23, 2020
REGULATORY Advisory Panel Shelves Decision on Avigan, Says No Clear Efficacy Shown for COVID-19

December 22, 2020
ORGANIZATION 3 Indicted Wholesalers Now Barred from National Hospital Organization Bids, Others Following Suit

December 21, 2020
REGULATORY Japan Saves 431.5 Billion Yen in Drug Price Cuts, Curbs Social Security Costs: FY2021 Draft Budget

December 21, 2020

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…

COMMENTARY

Hisamitsu’s MBO: Is Shareholder Accountability Trust-Building or a Shackle?

By Hayate Horiguchi

Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…